Opendata, web and dolomites


NeurescueTM: Computer- controlled aortic occlusion device for the treatment of cardiac arrest

Total Cost €


EC-Contrib. €






 CAtALySt project word cloud

Explore the words cloud of the CAtALySt project. It provides you a very rough idea of what is the project "CAtALySt" about.

brain    data    perfusion    surpass    with    premises    gathering    aps    aorta    10    below    portability    france    health    worldwide    commercial    2020    projected    sudden    catalyst    roll    234m    inside    denmark    rates    introduction    burden    standard    aggregated    light    works    odense    paris    total    neurescue    million    sca    profitable    patients    combines    intervention    united    window    outside    computer    arrests    vital    clinical    position    post    patient    back    hospital    emergency    university    severe    heart    2030    proposes    40    necker    roject    tissue    function    adoption    sensor    building    radically    damage    validation    company    competitive    medical    unrivalled    pressure    game    marking    accurate    generation    normal    barriers    safe    broad    predicted    changing    proposition    germany    preservation    probability    accuracy    time    aortic    algorithm    incidence    ce    survival    critical    synergy    market    assistance    chu    rate    89    resuscitation    ready    neur    demonstration    blood    device    23    public    run    neurescuetm    portable    samu    holding    price    business    solution    episodes    revenue    de    cardiac    organs    occlusion   

Project "CAtALySt" data sheet

The following table provides information about the project.


Organization address
address: NJALSGADE 76
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 2˙331˙787 €
 EC max contribution 1˙632˙251 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEURESCUE APS DK (KOBENHAVN) coordinator 1˙632˙251.00


 Project objective

With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2020 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- roject. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Clinical validation will be held at Odense University Hospital in Denmark, and further clinical evidence generation at Hospital SAMU de Paris CHU Necker in France, a leading university hospital in Germany, and a leading university hospital in the United States.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CATALYST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CATALYST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)


Read More